OJCD  Vol.4 No.1 , March 2014
Cardiac Amyloidosis: The Role of Magnetic Resonance Imaging
Abstract: Amyloidosis, an infiltrative disease characterized by deposition of high molecular weight insoluble protein has a low detection rate and poor prognosis with congestive heart failure being the most common cause of death. Although definitive diagnosis is based on endomyocardial biopsy, this is rarely performed due to procedural risk and sampling error. Traditional non-invasive imaging, such as transthoracic echocardiography (TTE) and electrocardiogram (ECG) lacks sensitivity detecting the disease in its early stages. This case report demonstrates the utility of cardiac Magnetic Resonance Imaging in addition to traditional imaging modalities in this often clinically challenging problem.
Cite this paper: Sim, L. , Semsarian, C. , Celermajer, D. and Puranik, R. (2014) Cardiac Amyloidosis: The Role of Magnetic Resonance Imaging. Open Journal of Clinical Diagnostics, 4, 27-30. doi: 10.4236/ojcd.2014.41006.

[1]   Seeger, A., Klumpp, B., Kramer, U., Stauder, N.I., Fenchel, M., Claussen, C.D. and Miller, S. (2009) MRI Assessment of Cardiac Amyloidosis: Experience of Six Cases with Review of the Current Literature. The British Journal of Radiology, 82, 337-342.

[2]   Halwani, O. and Delgado, D.H. (2010) Cardiac Amyloidosis: An Approach to Diagnosis and Management. Expert Review of Cardiovascular, 8, 1007-1013.

[3]   Mussi, T.C., Szarf, G., Furtado, P.G.R., Duarte, F., Nakano, E., Pinetti, R., Szejnfeld, D., Franco, M.F., Antonio Carlos de, C., Carvalho, C. and Ajzen, S.A. (2010) Cardiac Amyloidosis Secondary to Multiple Myeloma. European Journal of Radiology Extra, 75, e13-e16.

[4]   Wang, J., Kong, X., Xu, H., Zhou, G., Chang, D., Liu, D., Zhang, L. and Xie, M. (2010) Noninvasive Diagnosis of Cardiac Amyloidosis by MRI and Echocardiography. Journal of Huazhong University of Science and Technology [Medical Science], 30, 536-540.

[5]   Pennell, D.J. and Maceira, A.M. (2009) Magnetic Resonance Imaging in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2, 1369-1380.

[6]   Lang, M.R., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., Picard, M.H., Roman, M.J., Seward, J., Shanewise, J.S., Solomon, S.D., Spencer, K.T., St John Sutton, M. and Stewart, W.J. (2005) Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. Journal of the American Society of Echocardiography, 18, 1440-1463.

[7]   Garcia-Pavia, P., Tome-Esteban, M.T. and Rapezzi, C. (2011) Amyloidosis. Also a Heart Disease. Revista Espanola de Cardiología, 64, 797-808.

[8]   Rudski, L.G., Lai, W.W., Afilalo, J., Hua, L., Handschumacher, M.D., Chandrasekaran, K., Solomon, S.D., Louie, E.K. and Schiller, N.B. (2010) Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. Journal of The American Society of Echocardiography, 23, 685-713.

[9]   Wassmuth, R., Abdel-Aty, H., Bohl, S. and Schulz-Menger, J. (2011) Prognostic Impact of T2-Weighted CMR Imaging for Cardiac Amyloidosis. European Radiology, 21, 1643-1650.

[10]   Falk, R.H. and Dubrey, S.W. (2010) Amyloid Heart Disease. Progress in Cardiovascular Diseases, 52, 347-361.

[11]   Maredia, N. and Ray, S. (2005) Cardiac Amyloidosis. Clinical Medicine, 5, 504-509.

[12]   Mekinian, A., Lions, C., Leleu, X., Duhamel, A., Lamblin, N., Coiteux, V., De Groote, P., Hatron, P.-Y., Facon, T., Beregi, J.-P., Hachulla, E. and Launay, D. (2010) Prognosis Assessment of Cardiac Involvement in Systemic AL Amyloidosis by Magnetic Resonance Imaging. The American Journal of Medicine, 123, 864-868.